When Mylan announced Thursday that it will take “immediate action” to reduce out-of-pocket costs for patients that rely on the EpiPen, it was a last ditch effort to quiet the furor that has battered the company’s image and undercut its stock for …
Shareholders of the drugmaker Perrigo have shut the door on a $26-billion hostile takeover bid from Mylan. Mylan said that its cash-and-stock offer failed to garner enough interest from Perrigo shareholders by a Friday morning deadline to …
HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange …
Israel's Teva Pharmaceutical Tuesday launched an unsolicited bid to buy US pharmaceutical company Mylan for $40.1 billion in a transaction that would create a behemoth in generic drugs. Teva's cash-and-stock bid would quash an …
The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger …
Companies commonly give their executives incentives by linking their pay to earnings or stock-price goals, and companies are free to raise prices as they see fit. But some industry watchers say Mylan’s incentives may have played a role in …
Mylan N.V. MYL is scheduled to report second-quarter 2016 results on Aug 9, after market close. Mylan’s performance has been impressive with the company beating earnings estimates in three of the last four quarters. Overall, the …